Omeros Corp (OMER)

May 27, 2025, 11:12 PM EDT - 9 days ago

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

May 27, 2025, 7:20 AM EDT - 10 days ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

AGL ANIP

May 15, 2025, 9:07 PM EDT - 21 days ago

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:05 PM EDT - 21 days ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 24 days ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 24 days ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 4 weeks ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 11, 2025, 3:06 PM EDT - 7 weeks ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 10, 2025, 9:10 AM EDT - 2 months ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 2 months ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 8:57 PM EDT - 2 months ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:02 PM EDT - 2 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 28, 2025, 7:39 AM EDT - 2 months ago

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Mar 26, 2025, 9:15 AM EDT - 2 months ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 2 months ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 24, 2025, 4:44 PM EST - 3 months ago

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Feb 20, 2025, 9:10 AM EST - 3 months ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 4 months ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 4 months ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 5 months ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 12:28 PM EST - 6 months ago

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Dec 19, 2024, 9:15 AM EST - 6 months ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 10, 2024, 8:45 AM EST - 6 months ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 2, 2024, 8:45 AM EST - 6 months ago

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Nov 21, 2024, 9:15 AM EST - 7 months ago

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Nov 13, 2024, 10:22 PM EST - 7 months ago

Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:02 PM EST - 7 months ago

Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 4:11 PM EST - 7 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Oct 24, 2024, 8:45 AM EDT - 8 months ago

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Aug 10, 2024, 1:05 AM EDT - 10 months ago

Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:02 PM EDT - 10 months ago

Omeros Corporation Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:02 PM EDT - 10 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Jun 4, 2024, 9:00 AM EDT - 1 year ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

May 15, 2024, 7:23 PM EDT - 1 year ago

Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2024 Financial Results

May 10, 2024, 8:50 AM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024

May 9, 2024, 8:50 AM EDT - 1 year ago

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

Apr 1, 2024, 8:09 PM EDT - 1 year ago

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

Feb 20, 2024, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Feb 1, 2024, 9:11 AM EST - 1 year ago

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

Nov 27, 2023, 1:18 AM EST - 1 year ago

Omeros: Why It Is Worthwhile To Bet On Narsoplimab

Nov 10, 2023, 10:32 AM EST - 1 year ago

Omeros Corporation (OMER) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 4:02 PM EST - 1 year ago

Omeros Corporation Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 8:00 AM EST - 1 year ago

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023

Nov 3, 2023, 9:05 AM EDT - 1 year ago

Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Oct 19, 2023, 8:30 AM EDT - 1 year ago

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Oct 16, 2023, 8:02 AM EDT - 1 year ago

Omeros to terminate kidney disease trial as therapy fails late-stage study